Search
Gallium citrate Ga-67
go.drugbank.com/drugs/DB06784ApprovedGallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. … Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation
Estetrol
go.drugbank.com/drugs/DB12235ApprovedInvestigational[L33184] Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception. … [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]
Categories: Hormonal Contraceptives for Systemic UseRemestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with … with first-line therapies, putting them in a risk for poor outcomes and creating a significant clinical challenge [A31818].
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalanalgesic treatment for moderate to severe pain in adult patients with advanced cancer [L886]. … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: leafPro CBDmed Oil T-FS QD 5%, leafPro CBDmed Oil T-FS QD 20%Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnThe drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeClopidogrel
go.drugbank.com/drugs/DB00758ApprovedInvestigational[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and … in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and
Mixtures: CO-DEGREGANAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseReslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalBy targeting the IL-5 and disrupting its signalling pathways, reslizumab aims to inhibit eosinophil maturation and promote programmed cell death [A31578]. … In four double-blind, randomized, placebo‑controlled trials in patients with severe asthma on currently available therapies, patients receiving reslizumab had fewer asthma attacks, and a longer time to
Categories: Drugs for Obstructive Airway DiseasesSermorelin
go.drugbank.com/drugs/DB00010ApprovedWithdrawnSermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing … hormone (GHRH or GRF) consisting of 44 amino acid residues
Categories: Tests for Pituitary FunctionHydroxyprogesterone caproate
go.drugbank.com/drugs/DB06789ApprovedHydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. … In April 2023, the FDA withdrew its approval of Makena and its generics given an unfavorable risk-to-benefit assessment.[L46113]
Categories: Hormonal Contraceptives for Systemic Use